Our services span the entire lifecycle of product
development and commercialisation, and can be adapted to
suit small local trials or large global programs.
Site and patient identification, enrolment and engagement
Integrated services that cover planning, management, execution and analysis.
We have extensive experience in a broad range of therapeutic
areas. Managing studies in all major geographies, we have
established solid working relationships with the world’s
ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.
ICON has recently led the development of 14 vaccines resulting in FDA/EMA approvals
We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.
Using data to design, simulate, and analyse adaptive clinical trials with ease.
Digital solutions that increase efficiency in clinical trials by driving site performance.
BioPharma companies and Medical Devices manufacturers face
growing operational, regulatory and economic challenges. ICON
provides analysis and key insights on these challenges, with
practical advice and recommendations.
Remote monitoring and leveraging wearable devices and sensors in clinical trials.
Reduce post market study costs with Real World Data
ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.
Exploring the Innovative Use of Data to Enable Powerful Collaboration
Entering a New Era for Market Access
Our mission is to help clients accelerate the development of
drugs and devices that save lives and improve quality of life.
We are committed to exceeding the quality standards demanded by our clients, patients and regulatory authorities.
Partners Making a Difference.
Engage assay experts with unparalleled experience and expertise
Making it easier for the site and patient
Develop the right business strategy to successfully navigate MDR/IVDR
Primary research evaluating ICER’s influence over payers and manufactures
Digital health solutions for clinical R&D efficiency and patient outcomes
Insights you need for successful biosimilar commercialisation
Determine the right design, assessments and endpoints in your pain study
Social media and digital technology are providing new
opportunities for marketers by facilitating direct interaction
with patients and care partners.
Getting more connected with the patient and easing their
burden is really making a difference to enrollment rates.
The new MDR/IVDR will go into effect in 2020, greatly
increasing the complexity of keeping existing products on the
market and introducing new ones.
Exploring machine learning and natural language processing to maximize
RWE output using advanced computing.
Key takeaways from the EMA’s second draft guidance on MDR and its impact
on combination products.
Despite multiple challenges, RWE clearly has huge potential to
inform healthcare stakeholders.
Explore how conducting a thorough data-driven feasibility
assessment sets sponsors up for success in the operational
aspects of their trials.
ICON expert Dr. Uma Arumugam takes a look at the advancements in digital
applications and technology impacting clinical drug development.
ICON experts Bart Chapman and Shanthi Sundaramoorthy answer common questions about ophthalmology studies, and those relating to biosimilars.